Loading…
Lobbying Income
$292K
Filings
16
Unique Clients
2
Active Period
2022–2023
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2023 · fourth_quarter · Client: CALIFORNIA LIFE SCIENCES
Implementation of the Inflation Reduction Act (IRA) including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, the biosimilars marketplace, small molecule penalty and the small company exemption. Medicare and Medicaid changes in PBM legislation including Senate MEPA draft, HR 23561 PATIENT Act. CMS's proposed rule for Transitional Coverage of Emerging Technologies (TCET) - lobbied Congress to urge CMS to release the rule and lobbied in support for related legislation, the Ensuring Patient Access to Critical Breakthrough Products Act of 2023, H.R. 1691. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices.
Client expense: — · Firm income: $14,000
Matched citations: H.R. 1691
American Innovation and R&D Competitiveness Act of 2023
2023 · fourth_quarter · Client: CALIFORNIA LIFE SCIENCES
Lobbied in support of H.R. 2673, the American Innovation and R&D Competitiveness Act, and S. 866, the American Innovation and Jobs Act, to restore full deductibility of R&D spending.
Client expense: — · Firm income: $14,000
Matched citations: H.R. 2673
Preparedness and Response Reauthorization Act
2023 · fourth_quarter · Client: CALIFORNIA LIFE SCIENCES
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Client expense: — · Firm income: $14,000
Matched citations: HR 4420
Preparing for All Hazards and Pathogens Reauthorization Act
2023 · fourth_quarter · Client: CALIFORNIA LIFE SCIENCES
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Client expense: — · Firm income: $14,000
Matched citations: HR 4421
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Client expense: — · Firm income: $14,000
Matched citations: HR 830
Pharmacy Benefit Manager Transparency Act of 2023
2023 · fourth_quarter · Client: CALIFORNIA LIFE SCIENCES
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Client expense: — · Firm income: $14,000
Matched citations: S. 127
Pharmacy Benefit Manager Reform Act
2023 · fourth_quarter · Client: CALIFORNIA LIFE SCIENCES
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Client expense: — · Firm income: $14,000
Matched citations: S. 1339
Pandemic and All-Hazards Preparedness and Response Act
2023 · fourth_quarter · Client: CALIFORNIA LIFE SCIENCES
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Pandemics All Health Preparedness Act (PAHPA) reauthorization to ensure adequate funding and preparedness for programs including the National Health Security Strategy, the National Strategic Stockpile, and the Biomedical Advanced Research and Development Authority. Also lobbied for the inclusion of the PASTEUR Act in that bill. HR 4421/HR 4420 and S. 2333.
Client expense: — · Firm income: $14,000
Matched citations: S. 2333
American Innovation and Jobs Act
2023 · fourth_quarter · Client: CALIFORNIA LIFE SCIENCES
Lobbied in support of H.R. 2673, the American Innovation and R&D Competitiveness Act, and S. 866, the American Innovation and Jobs Act, to restore full deductibility of R&D spending.
Client expense: — · Firm income: $14,000
Matched citations: S. 866
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Client expense: — · Firm income: —
Matched citations: HR 3290
Inflation Reduction Act implementation issues including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, and the biosimilars marketplace. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices. Senate Finance Committee draft MEPA Act, HR 3561, PATIENT Act
Client expense: — · Firm income: —
Matched citations: HR 3561
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Client expense: — · Firm income: —
Matched citations: HR 3561
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Client expense: — · Firm income: —
Matched citations: HR 830
Pharmacy Benefit Manager Transparency Act of 2023
2023 · fourth_quarter · Client: AMGEN
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Client expense: — · Firm income: —
Matched citations: S. 127
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Client expense: — · Firm income: —
Matched citations: S. 1339
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Client expense: — · Firm income: —
Matched citations: HR 3290
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Client expense: — · Firm income: —
Matched citations: HR 3561
Inflation Reduction Act implementation issues including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, and the biosimilars marketplace. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices. Senate Finance Committee draft MEPA Act, HR 3561, PATIENT Act
Client expense: — · Firm income: —
Matched citations: HR 3561
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Client expense: — · Firm income: —
Matched citations: HR 830
Pharmacy Benefit Manager Transparency Act of 2023
2023 · fourth_quarter · Client: AMGEN
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Client expense: — · Firm income: —
Matched citations: S. 127
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Client expense: — · Firm income: —
Matched citations: S. 1339
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Client expense: — · Firm income: $22,500
Matched citations: HR 3290
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Client expense: — · Firm income: $22,500
Matched citations: HR 3561
Inflation Reduction Act implementation issues including Medicare Price Negotiation Program policies, including provisions in President Biden's FY 24 Budget Proposal to expand upon the scope of the Program, and the biosimilars marketplace. Medicare and Medicaid interactions in efforts to reform Pharmacy Benefit Manager (PBM) practices. Senate Finance Committee draft MEPA Act, HR 3561, PATIENT Act
Client expense: — · Firm income: $22,500
Matched citations: HR 3561
Lobbied on the importance of PBM transparency, oversight and reform on bills including S. 1339, the Pharmacy Benefit Manager Reform Act (on PBM issues overall and the inclusion of certain reporting requirements), S. 127, the Pharmacy Benefit Manager Transparency Act, HR 830, the HELP Copays Act (the importance of patient assistance and ensuring that the discounts are counted in OOP costs). Senate MEPA Act, HR 3561, the Patient Act 340B issues generally as potential amendments that could attach to any legislative vehicle in the House or the Senate. HR 3290, To Amend. Title III of the PHSA to ensure transparency and oversight of the 340B drug discount program.
Client expense: — · Firm income: $22,500
Matched citations: HR 830
Source: Senate LDA